AI Engines For more Details: Perplexity Kagi Labs You
Energy Production: D-ribose is a key component in the synthesis of ATP, which provides energy for various cellular processes. Supplementation with D-ribose may support ATP production, particularly in cells with high energy demands, such as heart and muscle cells.
Cardiovascular Health: D-ribose supplementation has been studied for its potential benefits in various cardiovascular conditions. It may improve exercise tolerance and reduce symptoms such as fatigue and shortness of breath in individuals with heart failure or coronary artery disease. D-ribose has also been investigated for its potential to support recovery after myocardial infarction (heart attack).
Exercise Performance and Recovery: Some research suggests that D-ribose supplementation may enhance exercise performance and improve recovery by replenishing ATP levels in muscles during intense physical activity. Athletes and individuals engaging in strenuous exercise may benefit from D-ribose supplementation to support energy production and reduce muscle fatigue.
Fibromyalgia and Chronic Fatigue Syndrome (CFS): D-ribose has been studied as a potential treatment for fibromyalgia and CFS, conditions characterized by chronic fatigue, muscle pain, and reduced exercise tolerance. Some studies have reported improvements in symptoms such as energy levels, sleep quality, and overall well-being with D-ribose supplementation. However, more research is needed to confirm these findings and establish optimal dosing regimens.
Mitochondrial Disorders: Mitochondrial disorders are a group of genetic conditions characterized by impaired mitochondrial function, leading to reduced ATP production and energy deficiency. D-ribose supplementation may help support ATP production and improve energy metabolism in individuals with mitochondrial disorders, although further research is needed to evaluate its efficacy in this population.
Neurological Health: D-ribose has been studied for its potential neuroprotective effects in conditions such as Parkinson's disease and traumatic brain injury (TBI). It may support neuronal energy metabolism and reduce oxidative stress, although more research is needed to fully understand its effects on neurological health.
Safety and Side Effects: D-ribose is generally considered safe when used at recommended doses. However, high doses of D-ribose may cause gastrointestinal discomfort, such as bloating, diarrhea, or nausea, in some individuals. As with any supplement, it's essential to follow dosage recommendations and consult with a healthcare professional before starting D-ribose supplementation, especially if you have underlying health conditions or are taking medications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
| species | Escherichia coli | Increases |
| strain | Escherichia coli G3/10 | Increases |
| strain | Escherichia coli Nissle 1917 | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.6 | |
| ADHD | 1.6 | -1.6 | |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.3 | 3 |
| Allergies | 0.5 | 1.2 | -1.4 |
| Allergy to milk products | 1.2 | 0.6 | 1 |
| Alzheimer's disease | 1.5 | 1.2 | 0.25 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | 0 |
| Ankylosing spondylitis | 0.3 | 2.1 | -6 |
| Antiphospholipid syndrome (APS) | 0.6 | -0.6 | |
| Asthma | 0.3 | 0.9 | -2 |
| Atherosclerosis | 0.6 | -0.6 | |
| Atrial fibrillation | 0.9 | 1.2 | -0.33 |
| Autism | 2.5 | 1.8 | 0.39 |
| Barrett esophagus cancer | 0.3 | 0.6 | -1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.6 | 0.3 | 1 |
| Brain Trauma | 0.9 | -0.9 | |
| Carcinoma | 0.6 | 0.9 | -0.5 |
| Celiac Disease | 1.8 | 1.4 | 0.29 |
| Cerebral Palsy | 1.2 | -1.2 | |
| Chronic Fatigue Syndrome | 1.2 | 1.2 | 0 |
| Chronic Kidney Disease | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | -0.6 | |
| Chronic Urticaria (Hives) | 1.5 | -1.5 | |
| Coagulation / Micro clot triggering bacteria | 0.9 | -0.9 | |
| Colorectal Cancer | 0.6 | 1.5 | -1.5 |
| Constipation | 0.3 | -0.3 | |
| Coronary artery disease | 0.6 | 0.6 | |
| COVID-19 | 1.4 | 2.5 | -0.79 |
| Crohn's Disease | 0.9 | 2.1 | -1.33 |
| cystic fibrosis | 0.6 | 0.9 | -0.5 |
| deep vein thrombosis | 0.9 | -0.9 | |
| Depression | 2.6 | 2 | 0.3 |
| Dermatomyositis | 0.6 | 0.6 | |
| Eczema | 1.2 | 0.9 | 0.33 |
| Endometriosis | 0.6 | 1.5 | -1.5 |
| Eosinophilic Esophagitis | 0.6 | 0.6 | |
| Epilepsy | 0.6 | 0.9 | -0.5 |
| Fibromyalgia | 0.6 | 0.6 | |
| Functional constipation / chronic idiopathic constipation | 0.6 | 1.7 | -1.83 |
| gallstone disease (gsd) | 0.6 | 0.9 | -0.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | -0.6 | |
| Generalized anxiety disorder | 0.8 | 0.9 | -0.13 |
| Graves' disease | 0.3 | 0.6 | -1 |
| Halitosis | 0.6 | -0.6 | |
| Hashimoto's thyroiditis | 0.6 | 0.6 | 0 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.3 | 1.2 | -3 |
| hyperglycemia | 0.6 | 0.3 | 1 |
| Hyperlipidemia (High Blood Fats) | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 0.6 | 0.9 | -0.5 |
| Hypothyroidism | 0.6 | 0.6 | |
| IgA nephropathy (IgAN) | 0.6 | 0.6 | |
| Inflammatory Bowel Disease | 0.8 | 1.7 | -1.13 |
| Intelligence | 0.2 | -0.2 | |
| Irritable Bowel Syndrome | 1.2 | 2.1 | -0.75 |
| Liver Cirrhosis | 1.2 | 1.5 | -0.25 |
| Long COVID | 1.5 | 2.3 | -0.53 |
| Lung Cancer | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.6 | 0.6 | |
| ME/CFS without IBS | 0.6 | 0.6 | |
| Menopause | 0.2 | 0.6 | -2 |
| Metabolic Syndrome | 1.6 | 2.3 | -0.44 |
| Mood Disorders | 2.9 | 2.2 | 0.32 |
| multiple chemical sensitivity [MCS] | 0.6 | -0.6 | |
| Multiple Sclerosis | 0.8 | -0.8 | |
| Multiple system atrophy (MSA) | 0.8 | 0.8 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | -0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.6 | 1 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | |
| Obesity | 0.8 | 1.1 | -0.38 |
| obsessive-compulsive disorder | 0.8 | 1.5 | -0.88 |
| Osteoarthritis | 0.2 | 0.3 | -0.5 |
| Osteoporosis | 0.9 | -0.9 | |
| Parkinson's Disease | 1.1 | 1.7 | -0.55 |
| Polycystic ovary syndrome | 0.6 | 0.3 | 1 |
| Postural orthostatic tachycardia syndrome | 0.6 | 0.6 | |
| Premenstrual dysphoric disorder | 0.6 | -0.6 | |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Psoriasis | 2.1 | -2.1 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.2 | 1.5 | -0.25 |
| Rosacea | 0.6 | -0.6 | |
| Schizophrenia | 1.2 | 1.2 | 0 |
| Sjögren syndrome | 0.8 | 1.3 | -0.63 |
| Sleep Apnea | 0.9 | -0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.6 | -2 |
| Stress / posttraumatic stress disorder | 0.6 | 1.2 | -1 |
| Systemic Lupus Erythematosus | 0.6 | 0.9 | -0.5 |
| Tic Disorder | 0.6 | 0.6 | |
| Type 1 Diabetes | 0.4 | 0.9 | -1.25 |
| Type 2 Diabetes | 1.6 | 2.3 | -0.44 |
| Ulcerative colitis | 0.8 | 1.8 | -1.25 |
| Unhealthy Ageing | 0.6 | 0.6 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.